RESUMEN
BACKGROUND AND OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) is related to inflammation and oxidative stress. Probiotics and prebiotics are considered anti-inflammatory and antioxidative factors. In this study, we evaluated the effects of probiotic and/or prebiotic on oxidative stress and inflammatory markers in patients with NAFLD. METHODS AND STUDY DESIGN: Seventy-five NAFLD subjects were divided into four groups. The first group received a pro-biotic capsule of Bifidobacterium longum (B.L) and Lactobacillus acidophilus (L.A) (2 × 107 CFU/day), the second group received prebiotic (10 g/day inulin), the third group received pro-biotic and prebiotic, and the fourth group received placebo, for three months. Anthropometric, inflammatory and oxidative/ anti-oxidative indices were measured in all patients before and after the intervention. RESULTS: We showed that consumption of pro- and/or prebiotic compared to placebo is able to significantly decrease body weight, body mass index, waist and hip circumferences, tumour necrosis factor-α and increase serum levels of total antioxidant capacity in patients with NAFLD (p<0.01). There were not any significant differences between probiotic, prebiotic and co-administration of them on the mentioned parameters. Co-administration of pro- and prebiotic caused significant decrease of high-sensitive C-reactive protein (hs-CRP) compared to the placebo and other groups (p<0.01). Interlekin-6 and malondialdehyde were not significantly different among groups at the end of study. CONCLUSIONS: Probiotic or/and prebiotic supplementation can be effective for improvement of some anthropometric, inflammatory and oxidative indices in patients with NAFLD. Co-administration of pro- and prebiotic is more effective than probiotic and prebiotic alone in modifying hs-CRP in patients with NAFLD.
Asunto(s)
Inflamación/sangre , Inflamación/complicaciones , Enfermedad del Hígado Graso no Alcohólico/complicaciones , Estrés Oxidativo/efectos de los fármacos , Prebióticos/administración & dosificación , Probióticos/farmacología , Adulto , Antioxidantes/administración & dosificación , Antioxidantes/farmacología , Bifidobacterium longum , Biomarcadores/sangre , Índice de Masa Corporal , Peso Corporal , Proteína C-Reactiva/metabolismo , Femenino , Humanos , Inflamación/tratamiento farmacológico , Lactobacillus acidophilus , Masculino , Enfermedad del Hígado Graso no Alcohólico/sangre , Probióticos/administración & dosificación , Factor de Necrosis Tumoral alfa/sangre , Circunferencia de la CinturaRESUMEN
The association between Helicobacter pylori (HP) infection and concentration of folate or homocysteine are still unclear. The aim of the present study was to assess the effect of HP infection on folate and homocysteine concentrations in patients infected with HP and healthy participants. We also assessed dietary intakes of folate, vitamins B6 and B12 in two groups. In this case-control study, 44 participants with HP-infection and 46 healthy controls were studied. Participants were recruited from those referred to the central laboratory of Tabriz University of Medical Sciences. Blood samples were collected to determine serum folate and homocysteine levels. The presence of both IgG and IgA in serum was considered as HP positive. Dietary intakes were assessed in all participants by 24-hour dietary recalls by trained interviewers for three days. The mean concentration of serum folate was significantly lower in HP-positive patients than in controls (8.49 nmol/L vs. 10.95 nmol/L, respectively; P=0.01). Although the mean concentration of serum homocysteine differed between groups, statistical significance was missed (HP infected patients: 9.35 µmol/L; healthy participants: 8.96 µmol/L; P=0.064). Macro- and micronutrient intakes showed no significant difference between participants with and without HP infection. In logistic regression models, there was a negative correlation between folate concentration and HP infection even after controlling for confounding factors (OR=0.82; CI95%=0.79-0.97). In this study, authors showed that a negative association presents between HP infection and serum folate concentrations, but the homocysteine status was not differed significantly between HP-positive and HP-negative participants.
Asunto(s)
Dieta , Ácido Fólico/sangre , Infecciones por Helicobacter/sangre , Helicobacter pylori/aislamiento & purificación , Homocisteína/sangre , Estudios de Casos y Controles , Ácido Fólico/administración & dosificación , Infecciones por Helicobacter/microbiología , Humanos , Irán , Modelos Logísticos , Vitamina B 12/administración & dosificaciónRESUMEN
Breast cancer is the most commonly diagnosed invasive malignancy and first leading cause of cancer-related deaths in Iranian women. Based on silymarin's unique characteristics, its application in chemotherapy combined with doxorubicin can be effective to enhance the efficacy together with a reduced toxicity on normal tissues. The present study focus on evaluate the efficacy of silymarin in combination with doxorubicin, on viability and apoptosis of estrogen-dependent breast carcinoma cell line (MCF-7). After being cultured, MCF-7 cells were divided into 8 groups and treated as follows: 1st group received 75 µg silymarin, groups 2, 3, and 4 were treated with 10, 25, and 50 nM doxorubicin, respectively, and groups 5, 6, and 7 respectively received 10, 25, and 50 nM doxorubicin as well as 75 µg silymarin. Viability percentage and apoptosis of the cells were assessed with Trypan Blue staining after 16, 24, and 48 hours. Silymarin has a synergistic effect on the therapeutic potential of doxorubicin. Use of silymarin in combination with doxorubicin can be more effective on the therapeutic potential of doxorubicin and decreases its dose-limiting side effects.
Asunto(s)
Antibióticos Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Neoplasias de la Mama/patología , Doxorrubicina/farmacología , Extractos Vegetales/farmacología , Silybum marianum/química , Línea Celular Tumoral , HumanosRESUMEN
In pregnancy period, there is high risk of hepatic diseases and alcohol consumption increases such risk. Some pregnant mothers are not able to quit the habit of drinking alcohol or they are unaware of its dangers. Finding a drug which is effective and efficient in reducing ethanol misuse consequences during pregnancy can assist the decrease of harmful effects of this habit. The purpose of the current research is to investigate the effects of oral administration of silymarin in preventing consequences of ethanol consumption on the liver during pregnancy, using the rat animal model as well as biochemical findings and clinical symptoms. 45 female rats were randomly divided into 3 groups, each composed of 15 rats. After the first day of pregnancy, the study was performed as follows. The first group received distilled water. The second group was given ethanol equivalent to 35% of their total required calorie. Furthermore, the third group received the same amount of ethanol plus 200 mg/kg silymarin. In order to evaluate liver's activity, biochemical analysis was performed at days 1, 7, 14, and 21, to measure the amount of the enzymes ALT, AST, ALP, and bilirubin. The nutrition and clinical status of animal in the groups was studied and recorded 2 times daily. This study showed that silymarin's protective effects are expressed from the first day of treatment.